SAP to Showcase Digital Innovation at SAP Leonardo Live Event
WALLDORF, Germany, May 31, 2017 (GLOBE NEWSWIRE) -- SAP MARKETFLASH -- SAP SE (NYSE: SAP) today announced that registration is available for its first-ever global digital innovation conference, SAP Leonardo Live. With technologies like Internet of Things (IoT), machine learning, blockchain, Big Data and analytics converging to dramatically transform the way people live and work, the SAP event will showcase leading innovations, industry expertise and best-practice business cases from around the globe. SAP Leonardo Live will take place on July 11 and 12 at the Kap Europa Congress Center in Frankfurt, Germany. Registration is available at www.delegate.com/sap/leonardolive/2017/.
"We are assembling the world's leading companies, technology vendors and industry visionaries to examine both the enormous potential and the tangible business value that can be achieved through digital innovation," said Mala Anand, EVP, President, SAP Leonardo. "SAP Leonardo Live will set an industry standard for peer-to-peer networking, creating a productive environment for learning, exchanging ideas and thinking big about digital innovation."
Recently launched at SAPPHIRE NOW 2017 as SAP's new digital innovation system, SAP Leonardo brings together differentiating software capabilities in machine learning, the Internet of Things (IoT), Big Data, analytics and blockchain on SAP Cloud Platform together with SAP experience, deep process and industry knowledge, and advanced design thinking methodology. With dozens of industry awards and recognitions, each of these areas of SAP's portfolio can add tremendous value for our customers on their digital journey - but the real power is when they all work together.
SAP Leonardo is built on SAP Cloud Platform and harnesses SAP's deep process and industry expertise, extensive software portfolio and expertise in emerging technologies to help customers manage digital business transformation. While many organizations see the potential of faster innovation and higher profitability from adopting digital business models, they often lack clarity on where to begin and how to integrate new approaches within their existing business. At SAP Leonardo Live, SAP will convene its powerful community of customers, partners and the industry's leading voices to help attendees see and understand how to adopt digital innovation that can scale across the entire organization.
"At SAP Leonardo Live, attendees can learn from experts who have already started their digital transformation and are already using cutting edge technologies in their businesses," said Dr. Tanja Rueckert, President, IoT and Digital Supply Chain, SAP. "Companies of all sizes from diverse industries around the world will be on hand to share best practices, lessons learned, industry knowledge and business expertise. Attendees can experience these new technologies through hands-on workshops and discover how SAP solutions can enable new digital models."
The two-day event will connect leaders of the business world on one central stage, featuring more than 50 companies from all over the world to discuss their digital innovation strategies. Agenda highlights of SAP Leonardo Live include:
- A comprehensive overview of our SAP Leonardo digital innovation portfolio and its concrete benefits for business
- Best practices from SAP customers in multiple industries, including Adidas, Hewlett Packard Enterprise, Hilti, KAESER Kompressoren SE, and Stara
- Compelling use cases powered by SAP Leonardo to improve the way it makes, designs, plans, delivers and maintains products and assets across a global network
- Exclusive peer-to-peer discussions and networking with thought leaders and business and technology experts
- Design thinking experts to demonstrate how new technologies like machine learning, IoT, analytics can work seamlessly together for your organization.
Kathrin Eiermann, SAP, +49 6227 74 07 79, firstname.lastname@example.org, CET
Jim Dever, SAP, +1 (610) 661-2161, email@example.com, EDT
SAP News Center press room, firstname.lastname@example.org
Kyle Tildsley, PAN Communications, +1 (617) 503-4352, email@example.com, EDT
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP's future financial results are discussed more fully in SAP's filings with the U.S. Securities and Exchange Commission ("SEC"), including SAP's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
© 2017 SAP SE. All rights reserved.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see http://www.sap.com/corporate-en/legal/copyright/index.epx#trademark for additional trademark information and notices.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SAP Global Marketing via Globenewswire
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53 | Pressemelding
AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc
Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42 | Pressemelding
NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq
Colliers International Expands in Washington, D.C.18.10.2017 14:30 | Pressemelding
Acquisition of Beltway Real Estate Services Firm Strengthens Ongoing Commitment to the Region TORONTO and WASHINGTON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI)(TSX:CIGI) announced today the acquisition of leading tenant representation advisory firm Serten Advisors. With its office in Tysons Corner, the firm serves global, national, and regional clients with a highly skilled and experienced team of professionals that have more than 100 years of combined experience. "This strategic acquisition positions Colliers to gain additional market share and win new business in the vibrant and competitive Suburban DC markets," said Marty Pupil, Colliers International President | U.S. Brokerage. "Adding Steve and Paul and the rest of their talented leadership team to our existing group of professionals in the region will further position Colliers as the commercial real estate services firm of
InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC18.10.2017 14:00 | Pressemelding
InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs. The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC. Anti-fibrotic therapi
Kofax Wins "Most Innovative Solution for Banking Customer Authentication" Award for Third Consecutive Year18.10.2017 08:00 | Pressemelding
Grand Prix Banque & Innovation Honor Recognizes Kofax Mobile ID Customer Onboarding Solution and its Anti-Fraud Capabilities IRVINE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Kofax ®, a leading provider of software to simplify and transform the First Mile(TM) of business, today announced that Kofax Mobile ID(TM) has won "Most Innovative Solution for Banking Customer Authentication" in the 2017 Grand Prix Banque & Innovation Awards in Paris, France. Now in its fourth year, the Awards identify excellence and innovation in the banking sector. The program acknowledges technology companies that have launched and implemented the most outstanding banking-related software solutions, initiatives and projects in France over the past twelve months. This award highlights the new facial recognition and ID verificationfeatures of Kofax Mobile ID that determine the authenticity and validity of identification documents and their holders.
World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer18.10.2017 06:25 | Pressemelding
YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference from the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new advancements surrounding the discovery of PD-1 and PD-L1, including a discussion from the researcher credited with discovering PD-1, as well as interventions to prevent lung cancer and improve quality of life for lung cancer patients. Innovations in lung cancer treatment linked to the discovery of PD-1 Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared an update on how PD-1 blockers have been widely used to treat many types of cancers. After decades of study, research into PD-1 has led to breakthrough immunotherapy treatments that are being hailed as a "penicillin moment" in cancer treatment. "I believe that, just as a number of antibiotics developed in the wake of the discovery of penicillin now p
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom